Pre-transplant vascular disease marked the highest-risk kidney transplant recipients
Kidney transplantation remains the preferred treatment for many people with end-stage renal disease, but long-term survival after surgery is not determined by graft function alone. In this Taiwanese cohort, pre-existing vascular disease before transplantation separated patients into clearly different post-transplant risk groups. Diabetes, prior acute myocardial infarction, and prior stroke each tracked with higher rates of major adverse cardiovascular and cerebrovascular events and death after transplantation.
The study drew on raw data from the National Health Insurance Research Database and included 3,562 adults who underwent uncomplicated kidney transplantation between 1997 and 2013. Follow-up lasted a median of 7.7 years, with observation extending as long as 17 years, and the analysis captured 28,267 person-years in total. During that period, 703 patients died, 125 experienced non-fatal AMI, and 104 had non-fatal stroke. The event burden was substantial enough to make pre-transplant risk profiling clinically meaningful rather than merely academic.
One finding stood out immediately: hypertension and dyslipidemia did not show the same independent association with the composite outcome once the models were adjusted. The signal was concentrated in established atherosclerotic disease and diabetes.
Diabetes, prior MI, and stroke separated from other baseline risks
Baseline characteristics showed a relatively young transplant population by cardiovascular standards, yet the event rates still accumulated over time. Only 225 patients, or 6.3%, were older than 60 years, and 1,895 were men, accounting for 53.2% of the cohort. Just 853 patients, 23.9%, had waited less than one year for kidney transplantation. Those figures matter because they frame the burden of cardiovascular disease in a population that still had years of exposure after transplant to chronic risk factors, immunosuppression, and residual vascular injury.
In logistic regression, three pre-transplant conditions emerged as significant predictors of the primary composite outcome. Diabetes carried an odds ratio of 2.085, prior AMI an odds ratio of 2.568, and prior stroke an odds ratio of 4.376, each with P values below 0.001. The corresponding fully adjusted Cox model told the same story over time: diabetes was associated with a hazard ratio of 1.560, prior AMI with 1.692, and prior stroke with 2.226. These are not small shifts. A history of stroke before transplantation more than doubled the hazard of the composite endpoint after surgery.
The pattern is clinically intuitive. Diabetes accelerates endothelial dysfunction, microvascular injury, and diffuse atherosclerosis. Prior myocardial infarction and stroke identify patients whose vascular disease has already crossed into clinically manifest territory. After transplant, the hemodynamic stress of surgery, persistent cardiovascular risk, and chronic kidney disease-related vascular burden likely continue to act on that substrate.
Why the pre-transplant cardiovascular history mattered more than blood pressure or lipids
The absence of an independent association for hypertension and dyslipidemia should not be read as reassurance that those factors are harmless. Rather, in this dataset, they did not retain predictive strength after adjustment when compared with the larger signal from diabetes and established cardiovascular events. In practical terms, a history of atherosclerotic disease functioned as a stronger marker of future harm than risk factors that may have been treated, modified, or incompletely captured in claims data.
This distinction is especially important in transplant medicine, where preoperative decisions often rely on how much uncertainty can be reduced before the patient reaches the operating room. A candidate with controlled hypertension but no known vascular event does not resemble a candidate with diabetes plus prior stroke. The latter carries evidence of systemic vascular vulnerability that can translate into both cardiac and cerebrovascular complications long after transplantation.
The composite endpoint itself was broad enough to reflect real-world consequence. It included non-fatal AMI, non-fatal stroke, and all-cause death. Because death was included, the outcome captured the combined burden of cardiovascular disease and competing medical risk after transplant, not just isolated cardiac admissions.
The long tail of risk after kidney transplantation
Median follow-up of 7.7 years gave the analysis enough time to observe delayed events, which is critical in transplant care. Early perioperative risk is only one part of the story. Patients who survive the operation often live long enough for pre-existing coronary and cerebrovascular disease to reassert itself, particularly when metabolic complications, chronic inflammation, and immunosuppressive therapy continue to shape vascular risk.
The cohort design also strengthens the clinical value of the findings. Uncomplicated transplant recipients were included, which narrows some of the noise that can arise from immediate surgical complications. Even in that more stable group, the burden of prior diabetes and overt cardiovascular disease remained visible. In other words, the signal was present despite selecting for patients who had already reached transplantation without major procedural complications.
A hazard ratio of 2.226 for prior stroke means that transplant candidacy cannot be evaluated through renal criteria alone. Neurologic history belongs in the same conversation as graft compatibility, dialysis exposure, and immunologic risk. A prior AMI and a prior stroke are not historical footnotes; they are markers of a vascular biology that continues to matter after the kidney is transplanted.
What transplant teams can use from these data
These findings support preoperative cardiovascular risk stratification in kidney transplant candidates, especially those with diabetes or prior ischemic events. The strongest practical lesson is not that transplant should be withheld, but that the post-transplant pathway should be planned with vascular history front and center. Patients with prior AMI or stroke may warrant closer cardiovascular surveillance, more deliberate optimization of modifiable risk factors, and careful discussion of long-term prognosis before surgery.
The results also reinforce how much transplant medicine depends on more than graft survival. A functioning kidney can improve survival in end-stage renal disease, yet the benefit is filtered through baseline cardiovascular health. If a patient enters transplant with established coronary or cerebrovascular disease, the operation does not erase the preceding vascular trajectory.
No funding supported the study, and the retrospective design limits causal inference. Claims data can miss clinical detail, and the analysis could only adjust for available baseline factors. Still, the consistency across logistic and Cox models gives the main message weight: diabetes, prior AMI, and prior stroke marked the subgroup most likely to experience MACCE or death after kidney transplantation.